Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET

Thursday, September 17, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

CHENGDU, China, Aug. 31 TianyinPharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer andsupplier of modernized traditional Chinese medicine ("TCM") and genericpharmaceuticals in China, today announced that it will present at the Rodman &Renshaw Annual Global Investment Conference, to be held September 9-11, 2009,at the New York Palace Hotel in New York City.

Mr. Stewart Lor, Director, is scheduled to present at 10:50 am ET onFriday, September 11th, 2009 in the Kennedy I salon (4th Floor). Mr. AllenTang, assistant to the CEO, will join Mr. Lor for one-on-one meetings withconference attendees throughout the three-day event. The presentation willdiscuss the Company's diversified product portfolio, customer base addressablemarket, competitive landscape, and recent financial results. Mr. Lor willprovide additional details on the $126 billion government sponsored healthcarereform plan and its potential benefits to the Company's long-term growthstrategy.

Registration is mandatory. For more information on the conference, contactyour Rodman and Renshaw representative, or to register, please visithttp://www.rodmanandrenshaw.com/ or email Lily Khaykina atlk@rodmanrenshaw.com. Please book all one-on-one requests directly throughthe meeting software interface provided by Rodman and Renshaw.

Additionally, Mr. Lor and Mr. Tang will host meetings throughout the NewYork area on September 11, 2009. To request a meeting please contact Mr. MattHayden of HC International at 760-613-3695-271 or by email atmatt.hayden@hcinternational.net.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 39 products, 22 of which are listed in the highly selectiveNational Medicine Catalog of the National Medical Insurance program. Tianyinowns and operates two GMP manufacturing facilities and an R&D platformsupported by leading Chinese academic institutions. The Company has a pipelineof 40 pharmaceutical products pending approval. Tianyin has an extensivenationwide distribution network throughout China with a sales force of 720salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with twomanufacturing facilities and a total of 1,365 employees. For more informationabout Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts during the presentation areforward-looking statements that involve certain risks and uncertaintiesincluding but not limited to risks associated with the uncertainty of futurefinancial results, additional financing requirements, development of newproducts, government approval processes, the impact of competitive products orpricing, technological changes, the effect of economic conditions and otheruncertainties detailed in the Company's filings with the Securities andExchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO in China Tel: +86-158-2122-5642 Email: Allen.y.tang@gmail.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: matt.hayden@hcinternational.net Web: http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical Co. Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store